Patents by Inventor Brian A. Crowe
Brian A. Crowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957520Abstract: A surgical headlamp assembly which can be remotely actuated at a wearer's chest and is suitable for surgical applications may include a headpiece. The headpiece may be sizable and configurable for placement on the head of a wearer. A lamp may be provided on the headpiece. The lamp may include at least one light source. At least one battery may be provided on the headpiece. The lamp may electrically interface with the battery. A remote lamp control module may operationally interface with the battery and the lamp. The lamp control module may be configured to control emission of a light beam from the lamp. The remote lamp control module may be suspendable from the headpiece and deployable in front of the chest of the wearer. In typical application of the surgical headlamp assembly, the lamp control module may be worn on the chest of the wearer.Type: GrantFiled: April 15, 2022Date of Patent: April 16, 2024Inventors: Brian Crowe, Ryan Pizinger
-
Patent number: 11305000Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: January 19, 2018Date of Patent: April 19, 2022Assignees: Brookhaven Science Associates, LLC, The Research Foundation of State University of New York, Baxalta Incorporated, Baxalta GmbHInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20180296656Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: January 19, 2018Publication date: October 18, 2018Applicants: BROOKHAVEN SCIENCE ASSOCIATE, LLC, RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORKInventors: Brian A. Crowe, Ian Livey, Maria O'rourke, Michael Schwendinger, John J Dunn, Benjamin J Luft
-
Patent number: 9895434Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: February 22, 2016Date of Patent: February 20, 2018Assignees: Research Foundation of the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20160235830Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: February 22, 2016Publication date: August 18, 2016Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 9334311Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: November 12, 2013Date of Patent: May 10, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 9303073Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: November 12, 2013Date of Patent: April 5, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBH, Research Foundation of the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 9023367Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: July 11, 2013Date of Patent: May 5, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
-
Publication number: 20140141030Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: BAXTER INTERNATIONAL INC., Brookhaven Science Associates, LLC, Research Foundation of the State University of New York, BAXTER HEALTHCARE SAInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20140141029Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Publication number: 20140030284Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: July 11, 2013Publication date: January 30, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
-
Patent number: 8623376Abstract: The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Research Foundation for the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 8623375Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Publication number: 20120020973Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: May 13, 2011Publication date: January 26, 2012Applicants: BAXTER INTERNATIONAL INC., Brookhaven Sciences Associates, LLC, Research Foundation of the State University of New York, BAXTER HEALTHCARE S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20110293652Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: May 13, 2011Publication date: December 1, 2011Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 6872550Abstract: A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B. burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.Type: GrantFiled: April 29, 1994Date of Patent: March 29, 2005Assignee: Baxter Vaccine AGInventors: Ian Livey, Brian Crowe, Friedrich Dorner
-
Patent number: 6654802Abstract: A system and method for continuously monitoring neighboring network elements and determining physical connection topology and changes in topology among network elements. Each port in a network element capable of having physical connectivity to a port on an adjacent network element has a unique identification of the node and a unique identification of the port. The identification is both available to the network management system and continuously transmitted on the physical link between two ports in the network, thus identifying the transmitting port to the receiving port. As nodes and ports are added to or deleted from a network, a representation of the nodes or ports is added or removed from the network management system. The local operating program in each network element informs the network management system of changes, or changes are queried by a network management system.Type: GrantFiled: February 12, 1999Date of Patent: November 25, 2003Assignee: Sprint Communications Company, L.P.Inventors: Stephen Arthur Oliva, Brian Crowe
-
Patent number: 6486130Abstract: A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.Type: GrantFiled: June 27, 1996Date of Patent: November 26, 2002Assignee: Baxter Vaccine AGInventors: Ian Livey, Brian Crowe, Friedrich Dorner
-
Patent number: 6261629Abstract: Novel water-soluble free-flowing protein-fibre products are provided from cereal grains, such as wheat, free from starch, bran and low molecular weight degradation products thereof. Starch contaminants in soluble fractions of the cereal grains are removed by enzymatic degradation and separation. The protein to fibre ratio of the product may be modified by enzymatic treatment. Such materials are useful in a wide variety of food application.Type: GrantFiled: May 19, 1999Date of Patent: July 17, 2001Inventors: Giuseppe Mazza, Lei Gao, B. Dave Oomah, Donald O'Connor, Brian Crowe